Comparing Efficacy and Safety of CTO0303 in Pediatric Subjects

A Multi-center, Double-blind, Randomized, Parallel, Active-controlled, Non-inferior, Phase Ⅱb/Ⅲ Study to Evaluate the Safety and Efficacy of CTO0303

This is a prospective randomized study compared with active control arm.

This is a prospective randomized study compared with active control arm. The investigators compare the pupil size in subject when 30 minutes after administering IP (CTO0303 or active control).

Inclusion Criteria:

• Pediatric or adolescent subjects those who get a written consent both whom and their parents (or legally acceptable representative)
• Pediatric or adolescent subjects aged 4 to 15 years old based on date of written consent

Exclusion Criteria:

• Subjects with a history of severe systemic reaction or increased sensitivity to atropine
• Subjects with anterior segment disease that interferes with ophthalmological examination (ex. corneal scar, corneal opacity and others)
• Subjects administered mydriatic medication within 14 days prior to administration of Investigational Product
• Subjects with contact lens